Searched for
CIPLA SHARES RISE
Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Q4 earnings review: Motilal Oswal highlights broad-based beat on estimates, lists 6 sectors that exceeded expectationsMotilal Oswal said Q4 FY26 earnings surpassed expectations, with aggregate profits rising 16% year-on-year against its 8% estimate. Strong ...
- Is India Inc's CSR truly driving systemic change or just shifting funds?Corporate India is entering a new phase of CSR. Spending is expected to cross ₹1.2 lakh crore by 2035. Companies are shifting towards syste...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Ahead of Market: 10 things that will decide stock market action on FridayBSE Sensex and Nifty 50 extended gains for a second session, led by banking, metal and pharma stocks despite IT weakness. Analysts flagged ...
- NLC India shares rally 18% to fresh record high after Q4 net profit skyrockets 189% YoYNLC India shares rose to a record high on Thursday after the company posted a 189% YoY surge in Q4 net profit to Rs 1,394 crore. Revenue ro...
- Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked targetCipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despit...
- Cipla Q4 Results: Profit falls 55% YoY to Rs 555 crore; co declares Rs 13/sh dividendCipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...
- Stocks in news: Airtel, Tata Motors, Dr Reddy's, NTPC, Dixon TechnologiesMarkets faced selling pressure on Tuesday due to weak global cues and macroeconomic concerns, with the Nifty approaching support at 23,150....
- Ahead of Market: 10 things that will decide stock market action on ThursdayNifty 50 and BSE Sensex declined, snapping a three-day rally due to IT and FMCG losses. Rising India VIX signaled caution, though broader t...
- Cipla shares rise over 2% as Kotak forecasts better days ahead, upgrades rating to ‘buy’Cipla shares rose by 2.4% to Rs 1,483.40 on Tuesday after Kotak Institutional Equities upgraded the stock from "add" to "buy," with a targe...
- Cipla tanks 5% as promoters sell stake in block dealDr Y K Hamied, Chairman and MK Hamied, Vice Chairman who are Non-Executive Directors and promoters, have sold 2,01,69,756 shares, represent...
- Share market update: Pharma shares rise; Cipla gains 3%The Nifty Pharma index was trading 1.31 per cent up at 9203.2.
- Share market update: Pharma shares advance; Cipla rises 1%The Nifty Pharma index was trading 0.41 per cent up at 8111.75 .
- Share market update: Pharma shares advance; Cipla rises 2%The Nifty Pharma index was trading 0.6 per cent up at 8045.4 .
- Cipla shares rise after Vysov anti-diabetic drug acquisitionCipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the ...
- Share market update: Pharma shares trade higher; Cipla rises 2%Benchmark NSE Nifty50 index was down 23.05 points at 10,860.7 while BSE Sensex was 117.08 points at 36,123.92 around 12:17 pm.
- Share market update: Pharma shares bullish; Cipla rises around 3%Benchmark NSE Nifty50 index was up 67 points at 10,683.7 while BSE Sensex was up 219.65 points at 35,480.19 around 01:08 pm.
- Cipla surges on Tamiflu demandShares of Cipla were in the limelight Monday on expectations that Cipla’s drug used to treat the pandemic swine flu will be in demand acros...
Load More
